Abstract | BACKGROUND/AIMS: METHOD: RESULTS: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs- TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs- TnT. Time to peak was 1-2 days for both groups. In the DOX-treated women, hs- TnT showed significant peaks from precycle baseline, increases in precycle 1 to precycle 2 levels, and a cycle 1 to cycle 2 peak and area under the curve (AUC). hs- TnT increased from precycle (1, 4.6 ± 6.3 pg/mL) to a cycle 2 peak of 16.1 ± 15.0 pg/mL (p < 0.002). No increases were seen with the TRA treatment. Transient posttreatment increases in NT-proBNP were seen after both therapies. CONCLUSION: DOX was associated with increased pretreatment baseline, peak, and AUC hs- TnT levels. Both DOX and TRA acutely perturb NT-proBNP. Assessment of pre- and posttreatment hs- TnT could be a means of quantifying cumulative myocardial injury in the course of chemotherapy.
|
Authors | Pooja Advani, Jonathan Hoyne, Alvaro Moreno-Aspita, Marcia Dubin, Shelly Brock, Caroline Harlow, Saranya Chumsri, Thomas Suter, Joseph L Blackshear |
Journal | Chemotherapy
(Chemotherapy)
Vol. 62
Issue 6
Pg. 334-338
( 2017)
ISSN: 1421-9794 [Electronic] Switzerland |
PMID | 28704807
(Publication Type: Journal Article)
|
Copyright | © 2017 S. Karger AG, Basel. |
Chemical References |
- Antineoplastic Agents
- Peptide Fragments
- Troponin T
- pro-brain natriuretic peptide (1-76)
- Natriuretic Peptide, Brain
- Doxorubicin
- Trastuzumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Area Under Curve
- Breast Neoplasms
(drug therapy, pathology)
- Doxorubicin
(therapeutic use)
- Female
- Humans
- Immunoassay
- Middle Aged
- Natriuretic Peptide, Brain
(blood)
- Neoplasm Staging
- Peptide Fragments
(blood)
- ROC Curve
- Trastuzumab
(therapeutic use)
- Troponin T
(blood)
|